Bio-Techne (TECH) Q4 EPS Rises 8.2%

Bio-Techne (NASDAQ:TECH), a leading provider of life sciences tools and diagnostic solutions, reported its earnings for the fourth quarter of fiscal 2025 on August 6, 2025. The company’s headline news was a modest beat on both revenue and non-GAAP earnings per share, with GAAP revenue of $317.0 million surpassed analyst expectations and non-GAAP earnings per share reaching $0.53. However, the company posted a GAAP loss following an $83.1 million impairment tied to the divestiture of its Exosome Diagnostics business. The current quarter saw a slowdown in organic revenue growth, an ongoing margin squeeze in some business units, and continued uncertainty in several end markets. Overall, the period reflected disciplined expense control and operational resilience, albeit with notable one-time charges and softer-than-usual growth. Source: Analyst estimates for the quarter provided by FactSet. Bio-Techne develops and supplies specialized products and solutions that enable scientific research and clinical diagnostics in the life sciences sector. Its core product offerings serve pharmaceutical companies, academic labs, and diagnostics labs with a broad portfolio including research proteins, analytical instruments, and diagnostic reagents. The company’s business model is anchored in recurring consumables sales and continuous product innovation.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool